96 related articles for article (PubMed ID: 2656331)
21. [Effect of PSK on recurrence of stage II/III gastric cancer].
Tanaka H; Muguruma K; Kubo N; Amano R; Noda E; Yamada N; Yashiro M; Maeda K; Sawada T; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2258-60. PubMed ID: 21224540
[TBL] [Abstract][Full Text] [Related]
22. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Iino Y; Yokoe T; Maemura M; Horiguchi J; Takei H; Ohwada S; Morishita Y
Anticancer Res; 1995; 15(6B):2907-11. PubMed ID: 8669887
[TBL] [Abstract][Full Text] [Related]
23. [Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators].
Ogoshi K; Mitomi T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1443-6. PubMed ID: 2586437
[TBL] [Abstract][Full Text] [Related]
24. [Experimental study on active specific immunotherapy utilizing the immune reaction of irradiated tumor tissue. 7. Effect of the cryopreserved immunoreactive cells combined with PSK].
Ogawa Y; Maeda T; Yoshida S; Yamamoto Y; Morita M; Imanaka K; Gose K; Imajo Y; Kimura S
Nihon Gan Chiryo Gakkai Shi; 1983 Apr; 18(3):682-5. PubMed ID: 6619634
[No Abstract] [Full Text] [Related]
25. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
26. Analysis of rare periparotid recurrence after parotid gland-sparing intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Xu Y; Zhang M; Yue Q; Zong J; Lin J; Sun R; Qiu S; Lin S; Pan J
Cancer Radiother; 2016 Jul; 20(5):377-83. PubMed ID: 27372558
[TBL] [Abstract][Full Text] [Related]
27. Treatment results of 59 young patients with nasopharyngeal carcinoma.
Selek U; Ozyar E; Ozyigit G; Varan A; Buyukpamukcu M; Atahan IL
Int J Pediatr Otorhinolaryngol; 2005 Feb; 69(2):201-7. PubMed ID: 15656953
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma. A significant factor in local control and distant metastasis.
Chua DT; Sham JS; Kwong DL; Choy DT; Au GK; Wu PM
Cancer; 1996 Jul; 78(2):202-10. PubMed ID: 8673993
[TBL] [Abstract][Full Text] [Related]
29. [The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs].
Fujisawa S; Suzumori K; Yasui Y; Yamamoto T; Yagami Y
Gan No Rinsho; 1986 Jan; 32(1):65-70. PubMed ID: 3485203
[TBL] [Abstract][Full Text] [Related]
30. [A case of remission in metastatic lung tumor from hepatocellular carcinoma after combined CDDP and PSK therapy].
Miyanaga O; Shirahama M; Ishibashi H
Gan No Rinsho; 1990 Mar; 36(4):527-31. PubMed ID: 1690825
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer.
Nio Y; Tsubono M; Tseng CC; Morimoto H; Kawabata K; Masai Y; Shiraishi T; Imai S; Ohgaki K; Tobe T
Biotherapy; 1992; 4(2):117-28. PubMed ID: 1622733
[TBL] [Abstract][Full Text] [Related]
32. [Administration of polysaccharide K (PSK) for stage III rectal cancer in clinical practice].
Ishibashi K; Hokama N; Ishiguro T; Kuwabara K; Okada N; Ohsawa T; Miyazaki T; Yokoyama M; Ishida H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1975-8. PubMed ID: 20037296
[TBL] [Abstract][Full Text] [Related]
33. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan.
Ogoshi K; Satou H; Isono K; Mitomi T; Endoh M; Sugita M
Cancer Invest; 1995; 13(4):363-9. PubMed ID: 7627722
[TBL] [Abstract][Full Text] [Related]
34. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.
Yu KH; Leung SF; Tung SY; Zee B; Chua DT; Sze WM; Law SC; Kam MK; Leung TW; Sham JS; Lee AW; Au JS; Hui EP; Sze WK; Cheng AC; Yau TK; Ngan RK; Wong FC; Au GK; Chan AT;
Head Neck; 2005 May; 27(5):397-405. PubMed ID: 15726589
[TBL] [Abstract][Full Text] [Related]
35. Effect of PSK on cytotoxicity against sarcoma-180 in tumor-bearing mice.
Oguchi Y; Ando T; Matsunaga K; Fujii T; Yoshikumi C; Nomoto K
Anticancer Res; 1987; 7(4B):681-4. PubMed ID: 3499859
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of adjuvant immunochemotherapy in advanced gastric cancer].
Sakamoto J; Nakazato H
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2525-30. PubMed ID: 8279851
[TBL] [Abstract][Full Text] [Related]
37. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
38. Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.
Mickey DD
Cancer Chemother Pharmacol; 1985; 15(1):54-8. PubMed ID: 4006049
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of pretreatment serum level of endostatin to posttreatment distant metastasis in patients with advanced nasopharyngeal carcinoma].
Zhao ZJ; Mo HY; Zhang CQ; Qi B; Li J; Hong MH; Mai HQ
Ai Zheng; 2007 Nov; 26(11):1243-7. PubMed ID: 17991326
[TBL] [Abstract][Full Text] [Related]
40. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 31 patients and prognostic factors.
To EW; Lai EC; Cheng JH; Pang PC; Williams MD; Teo PM
Laryngoscope; 2002 Oct; 112(10):1877-82. PubMed ID: 12368634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
